CoChat

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1-3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1-4), platelet derived growth factor receptor α (PDGFRα), KIT, and RET. We examined the antitumor activity of lenvatinib against human thyroid cancer xenograft models in nude mice. Orally administered lenvatinib showed significant antitumor activity in 5 differentiated thyroid cancer (DTC), 5 anaplastic thyroid cancer (ATC), and 1 medullary thyroid cancer (MTC) xenograft models. Lenvatinib also showed antiangiogenesis activity against 5 DTC and 5 ATC xenografts, while lenvatinib showed in vitro antiproliferative activity against only 2 of 11 thyroid cancer cell lines: that is, RO82-W-1 and TT cells. Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2. Lenvatinib also inhibited the phosphorylation of RET with the activated mutation C634W in TT cells. These data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2014/638747

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Antitumor activity of lenvatinib in human thyroid cancer xenograft models in nude mice. Nude mice bearing tumor xenografts were treated orally once daily with either vehicle or lenvatinib at the indicated doses when tumor volumes reached between 100 and 300 mm3 (day 1). Each group consisted of 5 mice. The change in tumor volume in the treated group relative to that in the control group ΔT/C (%) was calculated as (ΔT/ΔC) × 100%, where ΔT and ΔC are the change in tumor volume for the treated and vehicle control group, respectively. (a) DTC xenograft models. ΔT/C on day 15. (b) ATC xenograft models. ΔT/C on day 15. (c) TT xenograft model. ΔT/C on day 29. Data are shown as means ± SD. *P < 0.05 compared with vehicle-treated mice.
Figure 1 Antitumor activity of lenvatinib in human thyroid cancer xenograft models in nude mice. Nude mice bearing tumor xenografts were treated orally once daily with either vehicle or lenvatinib at the indicated doses when tumor volumes reached between 100 and 300 mm3 (day 1). Each group consisted of 5 mice. The change in tumor volume in the treated group relative to that in the control group ΔT/C (%) was calculated as (ΔT/ΔC) × 100%, where ΔT and ΔC are the change in tumor volume for the treated and vehicle control group, respectively. (a) DTC xenograft models. ΔT/C on day 15. (b) ATC xenograft models. ΔT/C on day 15. (c) TT xenograft model. ΔT/C on day 29. Data are shown as means ± SD. *P < 0.05 compared with vehicle-treated mice.CC BY · PubMed Central
Figure 2 Antiangiogenesis activity of lenvatinib in human thyroid cancer xenograft models in nude mice. Nude mice bearing tumor xenografts were treated orally once daily with either vehicle or lenvatinib at the indicated doses when tumor volumes reached between 100 and 300 mm3 (day 1). Microvessel density (MVD) was analyzed by immunohistochemical staining of endothelial cells with an anti-mouse CD31 antibody within the resected tumor xenografts as described in Section 2. MVD is expressed as the average number of microvessels per mm2 in 5 regions of interest (ROIs). Each group consisted of 5 mice. Data are shown as means ± SD. *P < 0.05 compared with vehicle-treated mice. DTC: differentiated thyroid cancer, MTC: medullary thyroid cancer, and ATC: anaplastic thyroid cancer.
Figure 2 Antiangiogenesis activity of lenvatinib in human thyroid cancer xenograft models in nude mice. Nude mice bearing tumor xenografts were treated orally once daily with either vehicle or lenvatinib at the indicated doses when tumor volumes reached between 100 and 300 mm3 (day 1). Microvessel density (MVD) was analyzed by immunohistochemical staining of endothelial cells with an anti-mouse CD31 antibody within the resected tumor xenografts as described in Section 2. MVD is expressed as the average number of microvessels per mm2 in 5 regions of interest (ROIs). Each group consisted of 5 mice. Data are shown as means ± SD. *P < 0.05 compared with vehicle-treated mice. DTC: differentiated thyroid cancer, MTC: medullary thyroid cancer, and ATC: anaplastic thyroid cancer.CC BY · PubMed Central
Figure 3 Effect of the selective FGFR kinase inhibitor PD173074 on the FGFR signaling pathway in human DTC RO82-W-1 cells. (a) Western blot analysis of the expression of FGF receptors in vitro. Expression levels of FGF receptors in RO82-W-1 cells were compared to those in Nthy-ori 3-1 cells (normal thyroid cells). (b) Western blot analysis of the effects of PD173074 on the phosphorylation of FGFR1 and its downstream effectors. After starvation overnight, RO82-W-1 cells were treated with PD173074 at the indicated concentrations for 1 h and were then stimulated for 10 min with bFGF (20 ng/mL) and heparin before being lysed. (c) Antitumor activity of PD173074 against RO82-W-1 xenografts in nude mice. Nude mice bearing RO82-W-1 xenografts were treated orally once daily for 14 days with either vehicle or PD173074 at the indicated doses when tumor volumes reached about 300 mm3 (day 1). The tumor volume was measured on the indicated days after administrations. Each group consisted of 5 mice. Data are shown as means ± SD. *P < 0.05 compared with vehicle-treated mice.
Figure 3 Effect of the selective FGFR kinase inhibitor PD173074 on the FGFR signaling pathway in human DTC RO82-W-1 cells. (a) Western blot analysis of the expression of FGF receptors in vitro. Expression levels of FGF receptors in RO82-W-1 cells were compared to those in Nthy-ori 3-1 cells (normal thyroid cells). (b) Western blot analysis of the effects of PD173074 on the phosphorylation of FGFR1 and its downstream effectors. After starvation overnight, RO82-W-1 cells were treated with PD173074 at the indicated concentrations for 1 h and were then stimulated for 10 min with bFGF (20 ng/mL) and heparin before being lysed. (c) Antitumor activity of PD173074 against RO82-W-1 xenografts in nude mice. Nude mice bearing RO82-W-1 xenografts were treated orally once daily for 14 days with either vehicle or PD173074 at the indicated doses when tumor volumes reached about 300 mm3 (day 1). The tumor volume was measured on the indicated days after administrations. Each group consisted of 5 mice. Data are shown as means ± SD. *P < 0.05 compared with vehicle-treated mice.CC BY · PubMed Central
Figure 4 Effect of lenvatinib on FGFR1 signaling pathway in human DTC RO82-W-1 cells in vitro. After starvation overnight, RO82-W-1 cells were treated with vehicle (control), lenvatinib or sorafenib at the indicated concentrations for 1 h and were then stimulated for 10 min with bFGF (20 ng/mL) and heparin before being lysed. Western blot analyses of the phosphorylation of FGFR1 and its downstream effectors in RO82-W-1 cells were then performed and representative images were shown.
Figure 4 Effect of lenvatinib on FGFR1 signaling pathway in human DTC RO82-W-1 cells in vitro. After starvation overnight, RO82-W-1 cells were treated with vehicle (control), lenvatinib or sorafenib at the indicated concentrations for 1 h and were then stimulated for 10 min with bFGF (20 ng/mL) and heparin before being lysed. Western blot analyses of the phosphorylation of FGFR1 and its downstream effectors in RO82-W-1 cells were then performed and representative images were shown.CC BY · PubMed Central
Figure 5 Effect of lenvatinib on the phosphorylation of RET with an activating mutation or a rearrangement in vitro. (a) Western blot analyses of the phosphorylation of RET in human medullary thyroid TT cells. TT cells were seeded and cultured overnight. They were then treated with lenvatinib at the indicated concentrations for 1 h before being lysed. (b) Western blot analyses of the phosphorylation of KIF5B-RET fusion proteins in normal thyroid cells; Nthy-ori 3-1 transfectants overexpressing KIF5B-RET (wild-type) or KIF5B-RET (M918T). Nthy-ori 3-1 transfectants were cultured overnight and then treated with lenvatinib at the indicated concentrations for 1 h before being lysed. Western blot analyses of the phosphorylation of RET and its downstream effectors in Nthy-ori 3-1 transfectants were then performed and representative images were shown.
Figure 5 Effect of lenvatinib on the phosphorylation of RET with an activating mutation or a rearrangement in vitro. (a) Western blot analyses of the phosphorylation of RET in human medullary thyroid TT cells. TT cells were seeded and cultured overnight. They were then treated with lenvatinib at the indicated concentrations for 1 h before being lysed. (b) Western blot analyses of the phosphorylation of KIF5B-RET fusion proteins in normal thyroid cells; Nthy-ori 3-1 transfectants overexpressing KIF5B-RET (wild-type) or KIF5B-RET (M918T). Nthy-ori 3-1 transfectants were cultured overnight and then treated with lenvatinib at the indicated concentrations for 1 h before being lysed. Western blot analyses of the phosphorylation of RET and its downstream effectors in Nthy-ori 3-1 transfectants were then performed and representative images were shown.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. 2002, Cancer Research, 62, 5749

Cited by

Metadata

Authors
Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y.
Affiliations
  • Eisai (Japan) (JP)
  • Eisai (United States) (US)
Corresponding author
Funahashi, Yasuhiro
Venue
Journal of Thyroid Research
Publisher
Wiley
Published
2014
Volume
2014
Pages
1-13
ISSN
  • 2042-0072 (ISSN-L)
  • 2090-8067
OpenAlex
W2094109552
Cited by
475
References
50
Citations by year
2026: 18 · 2025: 22 · 2024: 49 · 2023: 69 · 2022: 57 · 2021: 69 · 2020: 52 · 2019: 53 · 2018: 38 · 2017: 17 · 2016: 18 · 2015: 12 · 2014: 1
FWCI
13.15
Type
journal article
Language
en
Open access
Locations
  • Journal of Thyroid Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
lenvatinib, thyroid cancer, angiogenesis inhibition, VEGF receptor signaling, FGFR1, RET, receptor tyrosine kinase inhibitors, anaplastic thyroid carcinoma, medullary thyroid carcinoma, differentiated thyroid cancer, xenograft models, antiproliferative activity, FRS2, KIT, PDGFRA

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.